Tag: risk-based monitoring

Metrics That Matter in Historical Performance Evaluation

September 5, 2025

Metrics That Matter in Historical Performance Evaluation Key Metrics to Evaluate Historical Performance of Clinical Trial Sites Introduction: Why Performance Metrics Drive Feasibility Decisions Historical performance evaluation is a cornerstone of modern site feasibility processes in clinical trials. It enables sponsors and CROs to identify high-performing sites, reduce startup risks, and meet regulatory expectations. ICH…

Historical Performance Review, Study Feasibility and Site Selection

Targeted Monitoring Triggered by Protocol Deviations

August 29, 2025

digi

Targeted Monitoring Triggered by Protocol Deviations How Protocol Deviations Trigger Targeted Monitoring in Clinical Trials Introduction: When Deviations Signal Oversight Gaps Protocol deviations are more than isolated compliance errors—they often serve as early warning signals of systemic gaps in clinical trial conduct. Regulatory agencies such as the FDA, EMA, and MHRA increasingly expect sponsors to…

Monitoring and Training Based on Deviations, Protocol Deviation and CAPA Management

Implementing Risk-Based Monitoring in Rare Disease Trials

August 20, 2025

digi

Implementing Risk-Based Monitoring in Rare Disease Trials How to Apply Risk-Based Monitoring in Rare Disease Clinical Research Why Risk-Based Monitoring Is Essential in Rare Disease Trials Risk-Based Monitoring (RBM) has become a cornerstone of modern clinical trial management, replacing traditional 100% on-site Source Data Verification (SDV) with a more strategic, data-driven approach. For rare disease…

Operational Challenges, Rare and Orphan Disease Trials

Decentralized Data Capture in Global Rare Disease Trials

August 20, 2025

digi

Decentralized Data Capture in Global Rare Disease Trials Transforming Rare Disease Clinical Trials with Decentralized Data Capture The Shift Toward Decentralized Data Models Global rare disease trials face significant logistical and operational challenges. With patients often scattered across different countries and continents, traditional on-site data collection models result in delays, cost overruns, and participant burden….

Data & Technology, Rare and Orphan Disease Trials

Regulatory Risk Assessment for Rare Disease Clinical Development

August 20, 2025

digi

Regulatory Risk Assessment for Rare Disease Clinical Development Planning for Regulatory Risk in Rare Disease Drug Development Introduction: Why Regulatory Risk Assessment Matters in Rare Disease Trials Rare disease clinical development faces unique regulatory uncertainties due to small patient populations, limited data, and high unmet medical needs. A proactive regulatory risk assessment is essential to…

Rare and Orphan Disease Trials, Regulatory Frameworks

Implementing Risk-Based Monitoring in Rare Disease Trials

August 18, 2025

digi

Implementing Risk-Based Monitoring in Rare Disease Trials Designing Risk-Based Monitoring Strategies for Rare Disease Clinical Trials Why Risk-Based Monitoring is Essential in Rare Disease Studies Rare disease trials face unique challenges that make traditional, intensive on-site monitoring inefficient and often unsustainable. Small patient populations, dispersed across numerous global sites, mean fewer patients per site and…

Operational Challenges, Rare and Orphan Disease Trials

Cost Control Strategies for Rare Disease Clinical Trials

August 14, 2025

digi

Cost Control Strategies for Rare Disease Clinical Trials Balancing Innovation and Efficiency: Cost Control in Rare Disease Trials The High Cost Landscape of Rare Disease Trials Rare disease clinical trials often require intensive resources, customized procedures, and complex logistics, making them significantly more expensive per patient than conventional trials. According to a Tufts CSDD analysis,…

Operational Challenges, Rare and Orphan Disease Trials

Vaccine Stability and Cold Chain Qualification Studies

August 10, 2025

digi

Vaccine Stability and Cold Chain Qualification Studies Vaccine Stability & Cold Chain Qualification: A Practical, Regulatory-Ready Playbook Why Stability and Cold Chain Qualification Matter—Linking Chemistry to Clinical Credibility Every vaccine trial lives or dies on product integrity. Stability studies tell you how long a lot remains within specification at labeled storage (e.g., 2–8 °C for protein/adjuvant…

Cold Chain Requirements, Vaccine Clinical Trials

Maintaining Vaccine Potency Through Cold Chain Integrity

August 8, 2025

digi

Maintaining Vaccine Potency Through Cold Chain Integrity Maintaining Vaccine Potency Through Cold Chain Integrity Why Cold Chain Integrity Is Non-Negotiable in Vaccine Trials In vaccine trials, potency is fragile currency. Most modern vaccines—protein/subunit, mRNA, and vector platforms—are temperature sensitive, and minor deviations can degrade antigen, destabilize lipids, or reduce infectivity of vector particles. A robust…

Cold Chain Requirements, Vaccine Clinical Trials

Comparing Humoral vs Cellular Immunity in Vaccines

August 7, 2025

digi

Comparing Humoral vs Cellular Immunity in Vaccines Humoral vs Cellular Immunity in Vaccine Trials: What to Measure, How to Compare, and When It Matters Humoral and Cellular Immunity—Different Jobs, Shared Goal Vaccine programs routinely track two arms of the adaptive immune system. Humoral immunity is quantified by binding antibody concentrations (e.g., ELISA IgG geometric mean…

Immunogenicity Assessments, Vaccine Clinical Trials